ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

DePuy, Johnson & Johnson Moving to Settle Pinnacle Hip Lawsuits


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

corporate lawyers

DePuy Orthopaedics has been moving quickly to settle hundreds of lawsuits over its Pinnacle metal-on-metal hip implants filed by both patients and several state governments.

As of Feb. 15, 2019, the Johnson & Johnson subsidiary faced more than 9,850 patient lawsuits in a Dallas federal court. Attorneys general of 46 states had also sued the company over deceptive marketing of its Pinnacle and ASR hip implants.

In addition, reports say the company is in talks to settle 17 lawsuits that are in the appeals process. Juries awarded $1.7 billion to plaintiffs in the lawsuits, though those amounts have been reduced to about $788 million.

The Pinnacle hip was part of a generation of metal-on-metal hips that became increasingly popular with artificial hip manufacturers around the turn of the 21st century. Both parts of the artificial joint were made of metal alloys.

The design promised long-term durability. But the devices could release metal ions with each motion. This was blamed for sometimes causing a type of metal poisoning called metallosis, which destroys bone, muscle and other tissue. It can also lead to loosening, dislocation and other complications.

Complications claimed in Pinnacle lawsuits

  • Metallosis
  • Pain
  • Dislocation
  • Loosening
  • Revision surgery to remove and replace hip implants

DePuy has defended the safety record of the Pinnacle hip. The company never recalled the metal-on-metal version of the implant, but it pulled the design off the market in 2013, citing slumping sales. Later versions of the hip did away with the metal-on-metal design.

People filed lawsuits after they developed complications that required surgeries to remove and replace faulty Pinnacle hips.

Injured by complications related to hip replacements? Get a Free Case Review

Report: $400 Million to Settle 3,300 Pinnacle Lawsuits

As of mid-February, people had filed 10,087 federal lawsuits over problems with DePuy’s Pinnacle hip implants. A total of 9,853 were still pending at the time.

Early lawsuits had been filed in different District Courts around the country, but a federal panel formed a multidistrict litigation and centralized the lawsuits in the United States District Court for the Northern District of Texas.

Bloomberg reported in December 2018 that DePuy was offering to settle roughly 3,300 of the lawsuits still pending against the company. The report suggested an average payment of about $125,000 per lawsuit, putting the total amount as high as $413 million.

The Bloomberg report relied on court documents filed in the multidistrict litigation. It marked the first time the public had heard of the company broaching the subject of a settlement since the earliest lawsuits were filed around 2011.

The amount is far below the $1.4 billion Stryker offered in 2014 and 2016 to settle roughly 3,500 lawsuits over its Rejuvenate and ABG II metal-on-metal hips. It’s also below the $4.4 billion DePuy offered to settle 9,800 lawsuits over its ASR hips between 2013 and 2015.

Even if all the Pinnacle lawsuits targeted for settlements do in fact settle it would leave more than 6,500 lawsuits over the devices still pending in court.

A DePuy spokeswoman declined Bloomberg’s request for comment.

U.S. District Judge Ed Kinkeade, who presides over the multidistrict litigation, said DePuy was not looking for a global settlement of all cases. Instead, it was attempting to negotiate individual settlements with lawyers who are representing some of the 3,300 lawsuits targeted in the settlement talks. The strategy is similar to the one Johnson & Johnson used to settle lawsuits over its transvaginal mesh.

Report: DePuy May Settle 17 Cases that Won $1.7 Billion in Verdicts

Legal publisher HarrisMartin reports DePuy may be willing to settle cases involving 17 people who won nine- and 10-digit jury awards in three of the four bellwether trials in the Pinnacle multidistrict litigation.

Jury awards in Pinnacle lawsuits

  • March 2016 — $502 million for five plaintiffs (reduced to $151 million, then set aside on appeal and set for retrial)
  • December 2016 — $1 billion for six plaintiffs (reduced to $543 million based on punitive damage limits)
  • November 2017 — $247 million for six plaintiffs (reduced to $245 million based on punitive damage limits)

The announcement came as the court was preparing to retry a case that had gone to trial in March 2016. The federal judge dismissed potential jurors and announced talks were underway, according to HarrisMartin. The talks are still in the early stages and no details of any settlement offers in these 17 particular lawsuits have been announced.

The bellwether cases were representative of the thousands of lawsuits in the multidistrict litigation. The cases were chosen by both sides, and the trials became test cases for the litigation. The outcomes of such trials can sometimes determine if both sides can reach a settlement and how much the settlement will be.

DePuy Pays States $120 Million in Pinnacle and ASR Lawsuits

In January 2019, Johnson & Johnson and DePuy agreed to pay $120 million to settle claims by 46 states that the company had used deceptive marketing tactics to sell metal-on-metal hips, including the Pinnacle model.

The states claimed DePuy made misleading claims that its metal-on-metal hips would last longer than other designs. The company recalled 93,000 ASR hips in 2010 after 12 percent of the devices had failed within five years. Usually, only 10 percent of hip implants fail in the first 15 years.

The agreement allowed DePuy to escape admissions of any liability or misconduct, but it required the company to continue monitoring people implanted with its Pinnacle and ASR hips.

Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By
Emily Miller
Emily Miller Managing Editor

6 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Bellon, T. (2019, January 22). J&J, U.S. States Settle Hip Implant Claims for $120 Million. Reuters. Retrieved from
  2. DelMonico, K. (2019, February 13). Final Nail in JnJ’s $1.7 Billion Pinnacle Hip Lawsuit. Orthopedics This Week. Retrieved from
  3. Densford, F. (2018, December 13). Report: J&J Willing to Pay More than $400M to Settle Pinnacle Hip Cases. MassDevice. Retrieved from
  4. Feeley, J. and Fisk, M.C. (2018, December 11). J&J Starts Settling Suits Over Pinnacle Hip Defect Claims. Bloomberg. Retrieved from
  5. HarrisMartin Publishing. (2019, February 7). DePuy, J&J to Settle 17 Pinnacle Hip Bellwether Cases, Jury in Texas Federal Retrial Dismissed. Retrieved from
  6. U.S. Judicial Panel on Multidistrict Litigation. (2019, February 15). MDL Statistics Report. Retrieved from
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's sponsors support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(877) 280-3908